GSK completes divestment of thrombosis brands and related manufacturing site to Aspen

Issued: London UK

GlaxoSmithKline (“GSK”) today completed the previously announced divestment of its thrombosis brands, Arixtra^TM and Fraxiparine^TM to the Aspen Group (Aspen) for £700 million, following regulatory approval of the transaction. The majority of commercial operations will formally transfer to Aspen on 1 January 2014 with the remainder, along with the Notre-Dame de Bondeville manufacturing site, transferring in mid-2014.

GSK – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.  For further information please visit www.gsk.com.

About Aspen – Aspen is a global supplier of branded and generic pharmaceutical products as well as consumer and nutritional products in selected territories.  The Group has a proud heritage dating back more than 160 years and today its products reach approximately 150 countries. Aspen is the largest pharmaceutical company listed on the JSE Limited (“JSE”), South Africa’s stock exchange. The Group has 22 manufacturing facilities at 16 pharmaceutical manufacturing sites on six continents and approximately 8,200 employees. For further information please visit http://www.aspenpharma.com/.